Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Comparison of PET-CT to Whole Body Diffusion Weighted MRI in the Diagnosis of Plasma Cell Dyscrasias

Faith E. Davies, MD, Rohan Samant, MD, Thomas J. Eluvathingal, Leo Rasche, MD, Amy Buros, PhD, Kristen Schemel, Edgardo J. Angtuaco, MD, Rudy L. Van Hemert, MD, Manoj Kumar, MD, James E McDonald, BS, MD, James A. Ntambi, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Niels Weinhold, PhD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 5375.

https://doi.org/10.1182/blood.V130.Suppl_1.5375.5375

Published: 2017

Journal Articles

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Leo Rasche, MD, Amy Buros, PhD, Niels Weinhold, PhD, Caleb K. Stein, MS, James E McDonald, Shweta S. Chavan, PhD, Edgardo Angtuaco, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 4431.

https://doi.org/10.1182/blood.V128.22.4431.4431

Published: 2016

Journal Articles

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

Antonio Branca, MD, Amy Buros, PhD, Donghoon Yoon, PhD, Larry J Suva, PhD, Niels Weinhold, PhD, Leo Rasche, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Cerisse Harcourt, APRN, OCN, Faith E Davies, MD, Frits van Rhee, MD PhD, Gareth J Morgan, MD PhD, Maurizio Zangari, MD

Blood (2016) 128 (22): 4516.

https://doi.org/10.1182/blood.V128.22.4516.4516

Published: 2016

Journal Articles

The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Amy Buros, PhD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 1138.

https://doi.org/10.1182/blood.V128.22.1138.1138

Published: 2016

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Charlotte Pawlyn, MB BChir, Michael Bright, PhD, Amy Buros, PhD, Caleb K. Stein, MS, Zoe Walters, PhD, Lauren Aronson, PhD, Fabio Mirabella, PhD, Martin F Kaiser, MD, John R Jones, MD, Brian A Walker, PhD, Graham H Jackson, MD PhD, Paul Clarke, PhD, Leif Bergsagel, MD, Paul Workman, PhD, Marta Chesi, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3289.

https://doi.org/10.1182/blood.V128.22.3289.3289

Published: 2016

Journal Articles

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

James E McDonald, Marcus M Kessler, Michael Gardner, Amy Buros, PhD, Sarah Waheed, MD, James Ntambi, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Nathan Petty, MS, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Alan Mitchell, Antje Hoering, Bart Barlogie, MD PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2015) 126 (23): 724.

https://doi.org/10.1182/blood.V126.23.724.724

Published: 2015

Journal Articles

Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines

Charlotte Pawlyn, MB BChir, Tim Chambers, Veronica Macleod, Daniel Sappington, Amy Buros, PhD, Caleb K. Stein, MS, Martin F Kaiser, MD, Rosemary Burke, Swen Hoelder, Gunnar Boysen, Ricky D Edmondson, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2015) 126 (23): 1792.

https://doi.org/10.1182/blood.V126.23.1792.1792

Published: 2015

NARROW

A Comparison of PET-CT to Whole Body Diffusion Weighted MRI in the Diagnosis of Plasma Cell Dyscrasias

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines

Email alerts

ASH Publications

American Society of Hematology

A Comparison of PET-CT to Whole Body Diffusion Weighted MRI in the Diagnosis of Plasma Cell Dyscrasias

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only